Company News September 7, 2023 Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases June 20, 2023 ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer May 4, 2023 ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond January 5, 2023 ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference September 12, 2022 Shape Therapeutics named one of Fierce Biotech’s “Fierce 15” Companies of 2022 May 12, 2022 Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting April 26, 2022 Shape Therapeutics Welcomes Google and Stripe Veterans Gayathri Rajan, Kelly Sims to its Board of Directors January 6, 2022 Shape Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference November 9, 2021 Shape Therapeutics Appoints David J. Huss, Ph. D., as Chief Scientific Officer and Lisa Taylor Ash, J. D., as General Counsel August 24, 2021 Shape Therapeutics enters into a strategic research collaboration with Roche to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications July 15, 2021 Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapy May 28, 2021 Shape Therapeutics to Present the Discovery of Muscle-Specific AAVs at the Jefferies 2021 Virtual Healthcare Conference